GWAG
VRTX icon

Garrett Wealth Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Garrett Wealth Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-77
Closed -$13K – 622
2019
Q3 		$13K Buy
+77
New +$13.6K 0.01% 251

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Garrett Wealth Advisory Group's VRTX Position: Q4 2019 in Review

Garrett Wealth Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 77 shares — an estimated $13K sold.

Garrett Wealth Advisory Group first reported a position in VRTX in Q3 2019 and held it in 1 quarter. The position peaked at $13K in Q3 2019. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Garrett Wealth Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Garrett Wealth Advisory Group sold 77 Vertex Pharmaceuticals shares in Q4 2019, an estimated $13K.
  • Garrett Wealth Advisory Group first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Garrett Wealth Advisory Group's Vertex Pharmaceuticals position peaked at $13K in Q3 2019.
  • 814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Garrett Wealth Advisory Group's 13F filing for Q4 2019, filed 28 Jan 2020.